Abstract:<section class="article-section__content"><h3 class="article-section__sub-title section1"> Background</h3><p>Patient‐derived organoid (PDO) models are highly valuable and have potentially widespread clinical applications. However, limited information is available regarding organoid models of non‐small cell lung cancer (NSCLC). This study aimed to characterize the consistency between primary tumors in NSCLC and PDOs and to explore the applications of PDOs as preclinical models to understand and predict treatment response during lung cancer.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Methods</h3><p>Fresh tumor samples were harvested for organoid culture. Primary tumor samples and PDOs were analyzed via whole‐exome sequencing. Paired samples were subjected to immunohistochemical analysis. There were 26 antineoplastic drugs tested in the PDOs. Cell viability was assessed using the Cell Titer Glo assay 7–10 days after drug treatment. A heatmap of log‐transformed values of the half‐maximal inhibitory concentrations was generated on the basis of drug responses of PDOs through nonlinear regression (curve fit). A total of 12 patients (stages I–III) were enrolled, and 7 paired surgical tumors and PDOs were analyzed.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Results</h3><p>PDOs retained the histological and genetic characteristics of the primary tumors. The concordance between tumors and PDOs in mutations in the top 20 NSCLC‐related genes was >80% in five patients. Sample purity was significantly and positively associated with variant allele frequency (Pearson <i>r </i> = 0.82, <i>P </i> = 0.0005) and chromosome stability. The in vitro response to drug screening with PDOs revealed high correlation with the mutation profiles in the primary tumors. </p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Conclusions</h3><p>PDOs are highly credible models for detecting NSCLC and for prospective prediction of the treatment response for personalized precision medicine.</p></section><section class="article-section__content"><h3 class="article-section__sub-title section1"> Key points</h3><p>Lung cancer organoid models could save precious time of drug testing on patients, and accurately select anticancer drugs according to the drug sensitivity results, so as to provide a powerful supplement and verification for the gene sequencing.</p></section>

Primary Human Non‐Small Cell Lung and Pancreatic Tumorgraft Models—Utility and Applications in Drug Discovery and Tumor Biology

Patient-derived Xenograft Models in Hepatopancreatobiliary Cancer

Assessment of a Novel VEGF Targeted Agent Using Patient-Derived Tumor Tissue Xenograft Models of Colon Carcinoma with Lymphatic and Hepatic Metastases

Patient-derived Human Tumour Tissue Xenografts in Immunodeficient Mice: a Systematic Review

Personalized Cancer Therapy Using a Patient-Derived Tumor Tissue Xenograft Model: a Translational Field Worthy of Exploring Further?

A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology

Animal models for modeling pancreatic cancer and novel drug discovery

Personalized Primary Tumor Xenograft Model Established for the Pre-Clinical Trial to Guide Postoperative Chemotherapy

Circulating tumor cells and CDX models as a tool for preclinical drug development

Patient-derived xenografts: a relevant preclinical model for drug development

Patient-derived cell line, xenograft and organoid models in lung cancer therapy

Challenges and Prospects of Patient-Derived Xenografts for Cancer Research

Expansion of Circulating Tumor Cells from Patients with Locally Advanced Pancreatic Cancer Enable Patient Derived Xenografts and Functional Studies for Personalized Medicine

The application of pancreatic cancer organoids for novel drug discovery

Orthotopic Models Using New, Murine Lung Adenocarcinoma Cell Lines Simulate Human Non-Small Cell Lung Cancer Treated with Immunotherapy

Genomic characteristics and drug screening among organoids derived from non‐small cell lung cancer patients

Personalizing non-small cell lung cancer treatment through patient-derived xenograft models: preclinical and clinical factors for consideration

Genomic characteristics and drug screening among organoids derived fromnon-small celllung cancer patients

Development of primary human pancreatic cancer organoids, matched stromal and immune cells and 3D tumor microenvironment models

Advancements in Preclinical Models of Pancreatic Cancer

Utility of patient-derived xenografts to evaluate drug sensitivity and select optimal treatments for individual non-small-cell lung cancer patients